Literature DB >> 28277409

Randomized Controlled Trial of Two Alcohol-based Preparations for Surgical Site Antisepsis in Colorectal Surgery.

Robyn B Broach1, Emily C Paulson, Charles Scott, Najjia N Mahmoud.   

Abstract

OBJECTIVE: To compare 2 alcohol-based, dual-action skin preparations for surgical site infection (SSI) prevention in elective colorectal surgery.
BACKGROUND: Colorectal surgery is associated with the highest SSI rate among elective surgical procedures. Although evidence indicates that alcohol-based skin preparations are superior in SSI prevention, it is not clear if different alcohol-based preparations are equivalent in clean-contaminated colorectal procedures.
METHODS: We performed a blinded, randomized, noninferiority trial comparing iodine povacrylex-alcohol (IPA) and chlorhexidine-alcohol for elective, clean-contaminated colorectal surgery. The primary outcome was the presence or absence of SSI, defined as superficial or deep SSI, within 30 days postdischarge. A 6.6% noninferiority margin was chosen.
RESULTS: Between January 2011 and January 2015, 802 patients were randomized with 788 patients included in the intent to treat analysis (396 IPA and 392 chlorhexidine-alcohol). The difference in overall SSI rate between IPA (18.7%) and chlorhexidine-alcohol (15.9%) was 2.8% (P = 0.30). The upper bound of the 2.5% confidence interval of this difference was 8.9%, which is greater than the prespecified noninferiority margin of 6.6%. Other endpoints, including individual SSI types, time to SSI diagnosis, and length of stay were not different between the 2 arms.
CONCLUSIONS: In patients undergoing elective, clean contaminated colorectal surgery, the use of IPA failed to meet criterion for noninferiority for overall SSI prevention compared with chlorhexidine-alcohol. Photodocumentation of wounds and rigorous tracking of outcomes up to 30 days postdischarge contributed to high fidelity to current standard SSI descriptions and wound classifications.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28277409     DOI: 10.1097/SLA.0000000000002189

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  5 in total

Review 1.  Prevention of fracture-related infection: a multidisciplinary care package.

Authors:  Willem-Jan Metsemakers; Jolien Onsea; Emilie Neutjens; Ester Steffens; Annette Schuermans; Martin McNally; Stefaan Nijs
Journal:  Int Orthop       Date:  2017-08-22       Impact factor: 3.075

2.  Multicentre, open-label, randomised, controlled clinical trial comparing 2% chlorhexidine-70% isopropanol and 5% povidone iodine-69% ethanol for skin antisepsis in reducing surgical-site infection after cardiac surgery: the CLEAN 2 study protocol.

Authors:  Matthieu Boisson; Pierre Corbi; Thomas Kerforne; Lionel Camilleri; Mathieu Debauchez; Pierre Demondion; Vedat Eljezi; Erwan Flecher; Didier Lepelletier; Pascal Leprince; Nicolas Nesseler; Jacques Yves Nizou; Jean Christian Roussel; Bertrand Rozec; Stéphane Ruckly; Jean-Christophe Lucet; Jean-François Timsit; Olivier Mimoz
Journal:  BMJ Open       Date:  2019-06-17       Impact factor: 2.692

3.  Cluster-randomized crossover trial of chlorhexidine-alcohol versus iodine-alcohol for prevention of surgical-site infection (SKINFECT trial).

Authors:  A Charehbili; M B G Koek; J C A de Mol van Otterloo; M W G A Bronkhorst; P van der Zwaal; B Thomassen; E J Waasdorp; J A Govaert; A Bosman; J van den Bremer; A J Ploeg; H Putter; A P Meijs; C J H van de Velde; W van Gijn; R J Swijnenburg
Journal:  BJS Open       Date:  2019-05-20

Review 4.  The gut microbiota and colorectal surgery outcomes: facts or hype? A narrative review.

Authors:  Annamaria Agnes; Caterina Puccioni; Domenico D'Ugo; Antonio Gasbarrini; Alberto Biondi; Roberto Persiani
Journal:  BMC Surg       Date:  2021-02-12       Impact factor: 2.102

Review 5.  Randomised Controlled Trials of Alcohol-Based Surgical Site Skin Preparation for the Prevention of Surgical Site Infections: Systematic Review and Meta-Analysis.

Authors:  Trisha N Peel; Eliza Watson; Sue J Lee
Journal:  J Clin Med       Date:  2021-02-09       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.